Application of carbon nanotubes against Gram-positive bacteria
Through the application of multi-wall carbon nanotubes, the problem of poor effect of existing antibacterial drugs on drug-resistant bacteria has been solved, and effective inhibition of Gram-positive bacteria and low-toxicity and high-efficiency antibacterial effects of drug-resistant Staphylococcus aureus have been achieved. , providing new antibacterial materials and data support for clinical practice.
Patent Information
- Application Number
- CN202211718035.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-12-29
AI Technical Summary
The limited effect of existing antibacterial drugs on drug-resistant bacteria has led to their limited use. It is urgent to develop new antibacterial materials to deal with drug resistance problems.
Multi-walled carbon nanotubes are used as new antibacterial materials to verify their antibacterial effect on Gram-positive bacteria through in vitro and in vivo experiments, especially the inhibitory ability of drug-resistant Staphylococcus aureus, and different dosage forms are prepared to improve their clinical application. .
Multi-walled carbon nanotubes significantly inhibited ten common pathogens and drug-resistant bacteria, especially the antibacterial rate of methicillin-resistant Staphylococcus aureus reached 100%, and showed low toxicity and high efficiency antibacterial in the in vivo lung infection model. Its role provides clinical data support for novel antibacterial materials and antibacterial spectrum.
Smart Images

Figure CN116019833B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of carbon nanotubes, and in particular to an application of carbon nanotubes in resisting Gram-positive bacteria. Background Art
[0002] Although the role of antimicrobial drugs in the treatment of bacterial diseases and the development of agriculture and animal husbandry cannot be ignored, the phenomenon of bacterial resistance / tolerance to antimicrobial drugs limits the use of existing antimicrobial drugs. The development of new antimicrobial materials is imminent, and the new use of old drugs and the antimicrobial effect of new materials are key directions that urgently need to be developed to deal with the problem of drug resistance in the context of the era of drug resistance. Summary of the invention
[0003] The present invention provides an application of carbon nanotubes against Gram-positive bacteria to solve the above-mentioned problems existing in the prior art. The antibacterial application of carbon nanotubes against Gram-positive bacteria not only provides a new antibacterial material for clinical anti-bacterial infection and anti-drug resistant bacterial infection, but also provides data support for the antibacterial spectrum of the multi-walled carbon nanotubes in the future.
[0004] According to a first aspect of the present invention, the present invention provides an application of carbon nanotubes against Gram-positive bacteria.
[0005] The carbon nanotubes involved in the present invention are a type of nanomaterial. In addition to having the nanomaterial properties and adsorption capacity of the material itself, the present invention mainly provides the antibacterial efficacy of carbon nanotubes against ten common pathogens and drug-resistant bacteria. Experimental findings show that carbon nanotubes can effectively inhibit Gram-positive bacteria and significantly inhibit drug-resistant strains, providing a new solution for the treatment of clinical drug-resistant bacterial infections.
[0006] Furthermore, the carbon nanotubes are selected from carbon nanotubes soluble in lipophilic solvents.
[0007] Furthermore, the carbon nanotubes are multi-walled carbon nanotubes.
[0008] In the above scheme, the present invention establishes an in vitro and in vivo antibacterial model of multi-walled carbon nanotubes, detects the antibacterial efficacy of the multi-walled carbon nanotubes against ten kinds of bacteria in vitro, and finds that the multi-walled carbon nanotubes have good antibacterial effects on five kinds of Gram-positive bacteria, but poor effects on Gram-negative bacteria, indicating that the multi-walled carbon nanotube material has in vitro anti-Gram-positive bacteria efficacy, and through in vivo experiments, it is concluded that the multi-walled carbon nanotubes show good antibacterial effects and safety for acute lung infection of drug-resistant Staphylococcus aureus in vivo. The antibacterial application of multi-walled carbon nanotubes against Gram-positive bacteria involved in the present invention not only provides new antibacterial materials for clinical anti-bacterial infection and anti-drug-resistant bacterial infection, but also provides data support for the antibacterial spectrum of the multi-walled carbon nanotubes in the future.
[0009] Furthermore, the diameter of the multi-walled carbon nanotube is 10nm-30nm.
[0010] Furthermore, the characteristic Raman spectrum of the multi-walled carbon nanotubes includes four characteristic peaks, located at 1250 cm -1 -1450cm -1 、1500cm -1 -1750cm -1 、2500cm -1 -2800cm -1 、2850cm -1 -3000cm -1 .
[0011] Furthermore, the multi-walled carbon nanotubes can be prepared by a graphite arc method, a catalytic pyrolysis method or a laser evaporation method.
[0012] Furthermore, the Gram-positive bacteria include Staphylococcus aureus and Listeria.
[0013] Furthermore, the Gram-positive bacteria include drug-resistant Gram-positive bacteria.
[0014] Furthermore, the Gram-positive bacteria include Staphylococcus aureus ATCC29213, methicillin-resistant Staphylococcus aureus MRSA ST9, methicillin-resistant Staphylococcus aureus MRSA AR1, methicillin-resistant Staphylococcus aureus MRSA T144 and Listeria 1344.
[0015] Furthermore, the Gram-positive bacteria is methicillin-resistant Staphylococcus aureus MRSA T144.
[0016] Furthermore, the application method is to add the carbon nanotubes into a culture medium containing the Gram-positive bacteria. The culture medium may be LB agar, MHA culture medium, or the like.
[0017] Further, the concentration of the carbon nanotubes in the culture medium is 125 μg / ml-500 μg / ml. Optionally, the concentration of the carbon nanotubes in the culture medium can be 125 μg / ml, 150 μg / ml, 175 μg / ml, 200 μg / ml, 225 μg / ml, 250 μg / ml, 275 μg / ml, 300 μg / ml, 325 μg / ml, 350 μg / ml, 350 μg / ml, 375 μg / ml, 400 μg / ml, 425 μg / ml, 450 μg / ml, 475 μg / ml or 500 μg / ml, etc. It can be understood that by limiting the concentration of the carbon nanotubes in the culture medium to a reasonable range value, an effective antibacterial effect can be achieved.
[0018] Furthermore, the antibacterial rate of the multi-walled carbon nanotubes against the Gram-positive bacteria is ≥50%.
[0019] Furthermore, the multi-walled carbon nanotubes have an antibacterial rate of 100% against methicillin-resistant Staphylococcus aureus MRSA T144 at a concentration of 500 μg / ml.
[0020] According to the second aspect of the present invention, the present invention also provides a use of the above-mentioned carbon nanotubes in anti-Gram-positive bacteria drugs.
[0021] Furthermore, the anti-Gram-positive bacteria drug can be prepared into various dosage forms by conventional methods in the art, such as tablets, pills, pellets, capsules, granules, powders, suppositories, powders, ointments, patches, injections, solutions, suspensions, sprays, lotions, drops, liniments and emulsions.
[0022] Advantages of the present invention:
[0023] The present invention provides an application of carbon nanotubes against Gram-positive bacteria. The application uses the prepared multi-walled carbon nanotube material to establish an in vitro and in vivo antibacterial model of carbon nanotubes. The antibacterial efficacy of the multi-walled carbon nanotubes against ten bacteria in vitro is detected. It is found that the multi-walled carbon nanotubes have good antibacterial effects on five Gram-positive bacteria, but poor effects on Gram-negative bacteria. These Gram-positive bacteria include drug-resistant Staphylococcus aureus and intracellular parasite Listeria. The MRSA T144 strain that is most sensitive to multi-walled carbon nanotubes is selected, and mice are infected with the strain to establish a lung infection model. The in vivo antibacterial effect of the multi-walled carbon nanotubes is further detected. It is found that at an effective antibacterial concentration, the multi-walled carbon nanotubes have low toxicity within 24 hours and have a good antibacterial effect. The multi-walled carbon nanotube material provided by the present invention has in vitro efficacy against Gram-positive bacteria, and shows good antibacterial effect and safety for acute lung infection caused by drug-resistant Staphylococcus aureus in vivo. The antibacterial effect of the multi-walled carbon nanotubes provided by the present invention not only provides a new antibacterial material for clinical anti-bacterial infection and anti-resistant bacterial infection, but also provides data support for the antibacterial spectrum of the multi-walled carbon nanotubes in the future. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0025] Figure 1is a transmission electron microscope image of the multi-walled carbon nanotube in Example 1 of the present invention;
[0026] Figure 2 is a Raman spectrum of the multi-walled carbon nanotubes in Example 1 of the present invention;
[0027] Figure 3 This is a diagram showing the antibacterial effect of multi-walled carbon nanotubes against 10 pathogens in Example 1 of the present invention;
[0028] Figure 4 This is a comparison chart of the antibacterial rates of multi-walled carbon nanotubes against 10 pathogens in Example 1 of the present invention;
[0029] Figure 5 This is a comparison chart of the survival rates of mice in the control group, treatment group and infection group in Example 2 of the present invention;
[0030] Figure 6 This is a comparison chart of the in vivo antibacterial rates of the multi-walled carbon nanotubes at different concentrations in Example 2 of the present invention on mice infected with MRSA T144. DETAILED DESCRIPTION
[0031] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Example 1 In vitro test
[0033] This example was performed by transmission electron microscopy ( Figure 1 ) and Raman spectroscopy ( Figure 2 ) in order to understand the size, morphology, structure, etc. of multi-walled carbon nanotubes.
[0034] like Figure 1 As shown, the diameter of the multi-walled carbon nanotube is 10 nm. Figure 2 As shown in the figure, the characteristic Raman spectrum of multi-walled carbon nanotubes includes four characteristic peaks, located at 1350 cm -1 、1600cm -1 、2700cm -1 、2850cm -1 .
[0035] This embodiment provides a new antibacterial application of multi-walled carbon nanotubes against Gram-positive bacteria. The application experiment steps include: S1, establishment of a method for detecting the antibacterial efficacy of multi-walled carbon nanotubes; S2, determination of the morphology and structure of multi-walled carbon nanotubes using scanning electron microscopy and Raman spectroscopy; S3, in vitro antibacterial efficacy detection of multi-walled carbon nanotubes; S4, in vivo antibacterial detection and safety detection of multi-walled carbon nanotubes on greater wax moth.
[0036] This example first establishes the detection of the in vitro antibacterial rate of multi-walled carbon nanotubes by spotting method. Figure 3 As shown, the antibacterial efficacy of multi-walled carbon nanotubes against ten common pathogens and drug-resistant bacteria was tested, including five Gram-positive bacteria: Staphylococcus aureus S.aureus ATCC29213, methicillin-resistant Staphylococcus aureus MRSA ST9, methicillin-resistant Staphylococcus aureus MRSA AR1, methicillin-resistant Staphylococcus aureus MRSA T144 strains, Listeria monocytogenes 1344 and five Gram-negative bacteria: Escherichia coli ATCC25922, Klebsiella pneumoniae 1202, Gallobacterium gallinarum, Acinetobacter baumannii ATCC17988, Pseudomonas aeruginosa PAO370. The sources of the above pathogens: from the storage of this laboratory.
[0037] The antibacterial experiment process is as follows: after fully mixing a certain concentration of multi-walled carbon nanotubes with pathogens, take 10 ml of the bacterial suspension and spot it on the LB plate or blood plate, observe the growth of the colony after 16 hours, and quantitatively calculate the inhibition rate of multi-walled carbon nanotubes of different concentrations on ten common pathogens by detecting the number of colonies on the spot method, so that the antibacterial effect of multi-walled carbon nanotubes can be intuitively observed.
[0038] Based on the above embodiments, Figure 4 As shown, the antibacterial test results found that multi-walled carbon nanotubes were anti-Gram-positive bacteria, and had the best antibacterial effect on methicillin-resistant Staphylococcus aureus MRSA T144.
[0039] Furthermore, this embodiment also provides a concentration-dependent antibacterial effect of multi-walled carbon nanotubes. The antibacterial efficiency of multi-walled carbon nanotubes increases gradually from 10% to 100% as the concentration of multi-walled carbon nanotubes increases from 125 μg / ml, 250 μg / ml, and 500 μg / ml.
[0040] Furthermore, by comparing the changes in the antibacterial rate of multi-walled carbon nanotubes, it was found that multi-walled carbon nanotubes were most sensitive to methicillin-resistant Staphylococcus aureus MRSA T144. At a concentration of 500 μg / ml, the antibacterial rate of multi-walled carbon nanotubes against MRSAT144 reached 100%.
[0041] Example 2 In vivo test
[0042] Based on Example 1, a mouse lung infection model was established using the strain MRSA T144, which is the most sensitive to multi-walled carbon nanotubes. 9 CFU / mouse) was dripped into the lungs of mice and infected with different concentrations of multi-walled carbon nanotubes for treatment 6 hours after infection. This further provides an effective detection of the antibacterial and safety of multi-walled carbon nanotubes in vivo. Seven groups of mice were randomly selected, with 6 mice in each group, and set up as a control group (blank control, saline, multi-walled carbon nanotubes alone), a treatment group (125μg / ml, 250μg / ml, 500μg / ml multi-walled carbon nanotubes for treatment for 0-96 hours), an infection group (MRSA T14410 9 CFUs infection 0-96 hours), and the above reagents for the control group and the treatment combination infection group were inoculated into the mice respectively.
[0043] Furthermore, if Figure 5 As shown, the control group (blank control, saline, multi-walled carbon nanotubes alone), the treatment group (125μg / ml, 250μg / ml, 500μg / ml multi-walled carbon nanotubes for 0-96 hours), the infection group (MRSA T144 10 9 CFUs infection 0-96 hours), the survival rate of mice, draw a survival curve, Figure 5 It can be seen that when the multi-walled carbon nanotubes were used to treat the bacterial infection, the mice survived within 24 hours, indicating that at the effective antibacterial concentration, the multi-walled carbon nanotubes had low toxicity within 24 hours.
[0044] On the basis of the above examples, based on the survival curve of mice, the safe use range of multi-walled carbon nanotubes was established, and an experimental scheme was formulated with a MRSA T144 infection time of 4 hours and a multi-walled carbon nanotube treatment time of 12 hours. The in vivo antibacterial rate of multi-walled carbon nanotubes at concentrations of 125 μg / ml, 250 μg / ml, and 500 μg / ml was tested respectively. Figure 6 As shown, it was found that the in vivo antibacterial rate of multi-walled carbon nanotubes was as high as over 50%, and still showed a concentration-dependent antibacterial pattern.
[0045] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. An application of carbon nanotubes in the preparation of a drug for resisting Gram-positive bacteria, characterized in that: The carbon nanotubes are multi-walled carbon nanotubes; the carbon nanotubes are selected from carbon nanotubes soluble in lipophilic solvents; the diameter of the multi-walled carbon nanotubes is 10 nm, and the characteristic Raman spectrum of the multi-walled carbon nanotubes includes four characteristic peaks, which are located at 1350 cm -1 、1600cm -1 、2700cm -1 、2850cm -1 ; The Gram-positive bacteria is methicillin-resistant Staphylococcus aureus MRSA T144; The application method is to add the carbon nanotubes into a culture medium containing the Gram-positive bacteria; the concentration of the carbon nanotubes in the culture medium is 125 μg / ml-500 μg / ml.
